{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:52:48Z","timestamp":1761511968458},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,7,20]],"date-time":"2004-07-20T00:00:00Z","timestamp":1090281600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Individual patient meta-analysis to determine the analgesic efficacy and adverse effects of single-dose rofecoxib in primary dysmenorrhoea.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Individual patient information was available from three randomised, double blind, placebo and active controlled trials of rofecoxib. Data were combined through meta-analysis. Number-needed-to-treat (NNT) for at least 50% pain relief and the proportion of patients who had taken rescue medication over 12 hours were calculated. Information was collected on adverse effects.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>For single-dose rofecoxib 50 mg compared with placebo, the NNTs (with 95% CI) for at least 50% pain relief were 3.2 (2.4 to 4.5) at six, 3.1 (2.4 to 9.0) at eight, and 3.7 (2.8 to 5.6) at 12 hours. For naproxen sodium 550 mg they were 3.1 (2.4 to 4.4) at six, 3.0 (2.3 to 4.2) at eight, and 3.8 (2.7 to 6.1) at 12 hours. The proportion of patients who needed rescue medication within 12 hours was 27% with rofecoxib 50 mg, 29% with naproxen sodium 550 mg, and 50% with placebo. In the single-dose trial, the proportion of patients reporting any adverse effect was 8% (4\/49) with rofecoxib 50 mg, 12% (6\/49) with ibuprofen 400 mg, and 6% (3\/49) with placebo. In the other two multiple dose trials, the proportion of patients reporting any adverse effect was 23% (42\/179) with rofecoxib 50 mg, 24% (45\/181) with naproxen sodium 550 mg, and 18% (33\/178) with placebo.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>Single dose rofecoxib 50 mg provided similar pain relief to naproxen sodium 550 mg over 12 hours. The duration of analgesia with rofecoxib 50 mg was similar to that of naproxen sodium 550 mg. Adverse effects were uncommon suggesting safety in short-term use of rofecoxib and naproxen sodium. Future research should include restriction on daily life and absence from work or school as outcomes.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1472-6874-4-5","type":"journal-article","created":{"date-parts":[[2004,7,22]],"date-time":"2004-07-22T06:22:54Z","timestamp":1090477374000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data"],"prefix":"10.1186","volume":"4","author":[{"given":"Jayne E","family":"Edwards","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R Andrew","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry J","family":"McQuay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,7,20]]},"reference":[{"key":"27_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0002-9343(88)90473-1","volume":"84","author":"MY Dawood","year":"1988","unstructured":"Dawood MY: Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhoea. American Journal of Medicine. 1988, 84: 23-29. 10.1016\/0002-9343(88)90473-1.","journal-title":"American Journal of Medicine"},{"key":"27_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.12968\/bjon.1996.5.8.480","volume":"5","author":"A Hewison","year":"1996","unstructured":"Hewison A, van den Akker OB: Dysmenorrhoea, menstrual attitude and GP consultation. British Journal of Nursing. 1996, 5: 480-4.","journal-title":"British Journal of Nursing"},{"key":"27_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1054-139X(98)00147-5","volume":"25","author":"TI Hillen","year":"1999","unstructured":"Hillen TI, Grbavac SL, Johnston PJ, Straton JA, Keogh JM: Primary dysmenorrhoea in young Western Australian women: prevalence, impact and knowledge of treatment. Journal of Adolescent Health. 1999, 25: 40-5. 10.1016\/S1054-139X(98)00147-5.","journal-title":"Journal of Adolescent Health"},{"key":"27_CR4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/0002-9378(93)90292-Q","volume":"169","author":"MY Dawood","year":"1993","unstructured":"Dawood MY: Nonsteroidal antiinflammatory drugs and reproduction. American Journal of Obstetrics and Gynecology. 1993, 169: 1255-65.","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"27_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/09513599509160464","volume":"9","author":"C Bieglmayer","year":"1995","unstructured":"Bieglmayer C, Hofer G, Kainz C, Reinthaller A, Kopp B, Janisch H: Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecological Endocrinolology. 1995, 9: 307-12.","journal-title":"Gynecological Endocrinolology"},{"key":"27_CR6","first-page":"137","volume":"4","author":"S Nigam","year":"1991","unstructured":"Nigam S, Benedetto C, Zonca M, Leo-Rossberg I, Lubbert H, Hammerstein J: Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids. 1991, 4: 137-41.","journal-title":"Eicosanoids"},{"key":"27_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1111\/j.1471-0528.1998.tb10210.x","volume":"105","author":"WY Zhang","year":"1998","unstructured":"Zhang WY, Li Wan Po A: Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. British Journal of Obstetrics and Gynaecology. 1998, 105: 780-9.","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"27_CR8","first-page":"CD001751","volume":"4","author":"J Marjoribanks","year":"2003","unstructured":"Marjoribanks J, Proctor M, Farquhar C: Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. Cochrane Database of Systematic Reviews. 2003, 4: CD001751.","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"27_CR9","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0029-7844(99)00360-9","volume":"94","author":"BW Morrison","year":"1999","unstructured":"Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B: Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstetrics & Gynecology. 1999, 94: 504-8. 10.1016\/S0029-7844(99)00360-9.","journal-title":"Obstetrics & Gynecology"},{"key":"27_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S0029-7844(02)02085-9","volume":"100","author":"SE Daniels","year":"2002","unstructured":"Daniels SE, Talwalker S, Torri S, Snabes MC, Recker DP, Verburg KM: Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstetrics & Gynecology. 2002, 100: 350-8. 10.1016\/S0029-7844(02)02085-9.","journal-title":"Obstetrics & Gynecology"},{"key":"27_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000072735","volume":"56","author":"K Malmstrom","year":"2003","unstructured":"Malmstrom K, Kotey P, Cichanowitz N, Daniels S, Desjardins PJ: Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecology Obstetrics Investigations. 2003, 56: 65-9. 10.1159\/000072735.","journal-title":"Gynecology Obstetrics Investigations"},{"key":"27_CR12","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999, 354: 1896-1900. 10.1016\/S0140-6736(99)04149-5.","journal-title":"Lancet"},{"key":"27_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0020-7292(03)00260-1","volume":"83","author":"I Sahin","year":"2003","unstructured":"Sahin I, Saracoglu F, Kurban Y, Turkkani B: Dysmenorrhea treatment with a single daily dose of rofecoxib. International Journal of Gynaecology and Obstetrics. 2003, 83: 285-91. 10.1016\/S0020-7292(03)00260-1.","journal-title":"International Journal of Gynaecology and Obstetrics"},{"key":"27_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, More RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomised clinical trials: is blinding necessary?. Controlled Clinical Trials. 1996, 17: 1-12. 10.1016\/0197-2456(95)00134-4.","journal-title":"Controlled Clinical Trials"},{"key":"27_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0304-3959(00)00234-7","volume":"86","author":"LA Smith","year":"2000","unstructured":"Smith LA, Oldman AD, McQuay HJ, Moore RA: Teasing apart quality and validity in systematic reviews: an example from acupuncture trials in chronic neck and back pain. Pain. 2000, 86: 119-132. 10.1016\/S0304-3959(00)00234-7.","journal-title":"Pain"},{"key":"27_CR16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0304-3959(99)00302-4","volume":"85","author":"DJ Gavaghan","year":"2000","unstructured":"Gavaghan DJ, Moore RA, McQuay HJ: An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain. 2000, 85: 415-424. 10.1016\/S0304-3959(99)00302-4.","journal-title":"Pain"},{"key":"27_CR17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0895-4356(99)00204-8","volume":"53","author":"J-L Tang","year":"2000","unstructured":"Tang J-L, Liu JLY: Misleading funnel plot for detection of bias in meta-analysis. Journal of Clinical Epidemiology. 2000, 53: 477-484. 10.1016\/S0895-4356(99)00204-8.","journal-title":"Journal of Clinical Epidemiology"},{"key":"27_CR18","doi-asserted-by":"publisher","first-page":"224","DOI":"10.7326\/0003-4819-107-2-224","volume":"107","author":"KA L'Abb\u00e9","year":"1987","unstructured":"L'Abb\u00e9 KA, Detsky AS, O'Rourke K: Meta-analysis in clinical research. Annals of International Medicine. 1987, 107: 224-233.","journal-title":"Annals of International Medicine"},{"key":"27_CR19","first-page":"50","volume-title":"In: Statistics with confidence \u2013 confidence intervals and statistical guidelines","author":"JA Morris","year":"1995","unstructured":"Morris JA, Gardner MJ: Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: Statistics with confidence \u2013 confidence intervals and statistical guidelines. Edited by: Gardner MJ, Altman DG. 1995, London, British Medical Journal Books, 50-63."},{"key":"27_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"RJ Cook","year":"1995","unstructured":"Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal. 1995, 310: 452-454.","journal-title":"British Medical Journal"},{"key":"27_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/bmj.315.7109.635","volume":"315","author":"MR Tram\u00e8r","year":"1997","unstructured":"Tram\u00e8r MR, Reynolds DJM, Moore RA, McQuay HJ: Impact of covert duplicate publication on meta-analysis: a case study. British Medical Journal. 1997, 315: 635-9.","journal-title":"British Medical Journal"},{"issue":"3","key":"27_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0304-3959(98)00140-7","volume":"78","author":"RA Moore","year":"1998","unstructured":"Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ: Size is everything-large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain. 1998, 78 (3): 209-216. 10.1016\/S0304-3959(98)00140-7.","journal-title":"Pain"},{"key":"27_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/archinte.1996.00440060089011","volume":"156","author":"KS Khan","year":"1996","unstructured":"Khan KS, Daya S, Jadad AR: The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med. 1996, 156: 661-666. 10.1001\/archinte.156.6.661.","journal-title":"Arch Intern Med"},{"key":"27_CR24","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/S0149-2918(02)80043-1","volume":"24","author":"I Milsom","year":"2002","unstructured":"Milsom I, Minic M, Dawood MY, Akin MD, Spann J, Niland NF, Squire RA: Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clinical Therapeutics. 2002, 24: 1384-400. 10.1016\/S0149-2918(02)80043-1.","journal-title":"Clinical Therapeutics"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-4-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6874-4-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-4-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-4-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:36:06Z","timestamp":1728304566000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/1472-6874-4-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,20]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,12]]}},"alternative-id":["27"],"URL":"https:\/\/doi.org\/10.1186\/1472-6874-4-5","relation":{},"ISSN":["1472-6874"],"issn-type":[{"type":"electronic","value":"1472-6874"}],"subject":[],"published":{"date-parts":[[2004,7,20]]},"assertion":[{"value":"23 March 2004","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"5"}}